Omada Health, Inc.
Omada Health provides virtual care between doctor visits for people enrolled in its health programs, with services designed to benefit employers, health plans, health systems, pharmacy benefit managers and other entities that cover the cost. Its business-to-business-to-consumer model sells programs directly to customers or through channel partners that resell them. Omada makes money from fees for its programs, which may be billed through electronic healthcare claims when supported by a member’s health plan. Its programs include cardiometabolic care for diabetes prevention and weight management, diabetes, hypertension and cholesterol; support for members using GLP-1 therapies; and virtual physical therapy for musculoskeletal conditions. Members use mobile and web applications, connected devices and support from care teams that include health coaches, specialists and licensed physical therapists. Omada is headquartered in South San Francisco, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $OMDA in the last 7 days.
DraftKings (DKNG) fell 29% after missing earnings estimates, while TransMedics (TMDX) rose 20.3% on better-than-expected results. Omada Health (OMDA) dropped 19.8% despite beating estimates. All three saw unusual options activity.
Barclays kept Omada Health's rating at Overweight but reduced its price target to $22 from $24, citing an 8.3% decrease. The new target suggests a 16.1% upside from the Nov 5 close of $18.95. Recent analyst price targets for Omada Health range from $19 to $35.
Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.
Recent OMDA coverage spans earnings, financial news and insider activity.
In the last 30 days, OMDA insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($249K). The most active reporter was Duffy Sean P., Chief Executive Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Shares are falling despite earnings beat, reflecting negative market reaction and bearish option flow.
Barclays kept Omada Health's rating at Overweight but reduced its price target to $22 from $24, citing an 8.3% decrease. The new target suggests a 16.1% upside from the Nov 5 close of $18.95. Recent analyst price targets for Omada Health range from $19 to $35.
Guidance suggests weaker near‑term growth and margin pressure.
Guidance raise suggests stronger growth trajectory.
The raised guidance signals stronger revenue growth and profitability, likely supporting the stock.
AlphAI scores every news story that mentions OMDA with an AI model for sentiment and relevance, and aggregates insider trades from Omada Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
DraftKings (DKNG) fell 29% after missing earnings estimates, while TransMedics (TMDX) rose 20.3% on better-than-expected results. Omada Health (OMDA) dropped 19.8% despite beating estimates. All three saw unusual options activity.
Barclays kept Omada Health's rating at Overweight but reduced its price target to $22 from $24, citing an 8.3% decrease. The new target suggests a 16.1% upside from the Nov 5 close of $18.95. Recent analyst price targets for Omada Health range from $19 to $35.
Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.
Omada Health reported Q3 2026 revenue of $91M, up 34% YoY, with 1.1M members, a 36% increase. Net income was $7M, reversing a $3M loss from Q3 2025. The company raised its full-year 2026 revenue outlook to $344M-$346M and adjusted EBITDA to $32M-$34M.
Omada Health, Inc. (OMDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Omada Health Reports Third Quarter 2026 Results • Quarterly Revenue of $91 million and All-Time High Total Members of 1.1 million • Revenue Grew 34% and Total Members Increased 36% Year over Year • Raises Full Year 2026 Financial Outlook SAN FRANCISCO - November 5, 2026 - Omada H
Citizens maintained a Market Outperform rating and $32 price target for Omada Health (NASDAQ:OMDA), citing its diversified solutions and growth prospects. The stock has risen 31% in six months, with 48% revenue growth in the past year. Q2 2026 revenue was $88M, up 43% YoY, with adjusted EPS of $0.08. The company raised its full-year revenue and EBITDA outlook, achieving GAAP profitability.
Omada Health (NASDAQ:OMDA) presented a 12-week study at the World Obesity and Weight Management Congress, showing its GLP-1 Care Track program led to 6.0% average weight loss vs. 3.3% for usual care. The study, published in Diabetes, Obesity and Metabolism, involved 245 adults with obesity. Omada's program also improved body composition, well-being, and reduced depression/anxiety symptoms.
Freedom Capital Markets reiterated a Buy rating and $35 price target for Omada Health, implying a 91.3% upside. The firm cites strong demand for Omada's integrated care solutions and resilience against competitors.
Omada Health (Nasdaq: OMDA) will release its Q3 2026 results on Nov. 5 after market close and host a conference call at 4:30 p.m. ET. The call will be webcast live and a replay will be available for 12 months. Omada Health is a virtual healthcare provider focusing on chronic conditions.
Duffy Sean P. (Chief Executive Officer) sold 21,572 shares of Omada Health, Inc. (OMDA) at an average of $23.62 ($23.12–$24.27, $0.51M total) across 4 trades on 2026-09-01 under a Rule 10b5-1 trading plan.
